Skip to main content

Mylan CEO Tries to Shift Focus

Amid numerous calls for state and federal investigations over pricing of its EpiPen, the drug company Mylan struck back, saying that 55 percent of the price goes to “middleman’’ insurers.

Lead image for this article

Amid numerous calls for state and federal investigations over pricing of its EpiPen, the drug company Mylan struck back, saying that 55 percent of the price goes to “middleman’’ insurers. (Becker’s Hospital Review)

Support public-service journalism that gets the context right

Yes, I'll donate today